OALib Journal期刊
ISSN: 2333-9721
费用：99美元

投递稿件

查看量	下载量

相关文章
Modulation of Bacterial Multidrug Resistance Efflux Pumps of the Major Facilitator Superfamily
Roles of Major Facilitator Superfamily Transporters in Phosphate Response in Drosophila
Function, Structure, and Evolution of the Major Facilitator Superfamily: The LacY Manifesto
Integration of Evolutionary Features for the Identification of Functionally Important Residues in Major Facilitator Superfamily Transporters
BC4707 Is a Major Facilitator Superfamily Multidrug Resistance Transport Protein from Bacillus cereus Implicated in Fluoroquinolone Tolerance
Major Facilitator Superfamily Domain-Containing Protein 2a (MFSD2A) Has Roles in Body Growth, Motor Function, and Lipid Metabolism
Teacher as Learning Facilitator in ELT
The practical theologian as decentred but influential facilitator
Trust: Facilitator of Knowledge-sharing Culture
Who helps an online facilitator to learn with students in a day?
更多...

PLOS ONE 2012

Basic Residues R260 and K357 Affect the Conformational Dynamics of the Major Facilitator Superfamily Multidrug Transporter LmrP

DOI: 10.1371/journal.pone.0038715

Wei Wang, Hendrik W. van Veen

Full-Text Cite this paper Add to My Lib

Abstract:

Secondary-active multidrug transporters can confer resistance on cells to pharmaceuticals by mediating their extrusion away from intracellular targets via substrate/H+(Na+) antiport. While the interactions of catalytic carboxylates in these transporters with coupling ions and substrates (drugs) have been studied in some detail, the functional importance of basic residues has received much less attention. The only two basic residues R260 and K357 in transmembrane helices in the Major Facilitator Superfamily transporter LmrP from Lactococcus lactis are present on the outer surface of the protein, where they are exposed to the phospholipid head group region of the outer leaflet (R260) and inner leaflet (K357) of the cytoplasmic membrane. Although our observations on the proton-motive force dependence and kinetics of substrate transport, and substrate-dependent proton transport demonstrate that K357A and R260A mutants are affected in ethidium-proton and benzalkonium-proton antiport compared to wildtype LmrP, our findings suggest that R260 and K357 are not directly involved in the binding of substrates or the translocation of protons. Secondary-active multidrug transporters are thought to operate by a mechanism in which binding sites for substrates are alternately exposed to each face of the membrane. Disulfide crosslinking experiments were performed with a double cysteine mutant of LmrP that reports the substrate-stimulated transition from the outward-facing state to the inward-facing state with high substrate-binding affinity. In the experiments, the R260A and K357A mutations were found to influence the dynamics of these major protein conformations in the transport cycle, potentially by removing the interactions of R260 and K357 with phospholipids and/or other residues in LmrP. The R260A and K357A mutations therefore modify the maximum rate at which the transport cycle can operate and, as the transitions between conformational states are differently affected by components of the proton-motive force, the mutations also influence the energetics of transport.

References

[1]	Piddock LJ (2006) Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 19: 382–402.
[2]	Nikaido H, Pages JM (2012) Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev 36: 340–363.
[3]	Yasufuku T, Shigemura K, Shirakawa T, Matsumoto M, Nakano Y, et al. (2011) Correlation of overexpression of efflux pump genes with antibiotic resistance in Escherichia coli strains clinically isolated from urinary tract infection patients. J Clin Microbiol 49: 189–194.
[4]	Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48–58.
[5]	Paulsen IT, Brown MH, Skurray RA (1996) Proton-dependent multidrug efflux systems. Microbiol Rev 60: 575–608.
[6]	Borges-Walmsley MI, McKeegan KS, Walmsley AR (2003) Structure and function of efflux pumps that confer resistance to drugs. Biochem J 376: 313–338.
[7]	Poole K (2005) Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56: 20–51.
[8]	van Veen HW, Konings WN (1997) Multidrug transporters from bacteria to man: similarities in structure and function. Semin Cancer Biol 8: 183–191.
[9]	Saier MH Jr, Paulsen IT (2001) Phylogeny of multidrug transporters. Semin Cell Dev Biol 12: 205–213.
[10]	Bolhuis H, Poelarends G, van Veen HW, Poolman B, Driessen AJ, et al. (1995) The lactococcal lmrP gene encodes a proton motive force-dependent drug transporter. J Biol Chem 270: 26092–26098.
[11]	Bolhuis H, van Veen HW, Brands JR, Putman M, Poolman B, et al. (1996) Energetics and mechanism of drug transport mediated by the lactococcal multidrug transporter LmrP. J Biol Chem 271: 24123–24128.
[12]	Bapna A, Federici L, Venter H, Velamakanni S, Luisi B, et al. (2007) Two proton translocation pathways in a secondary active multidrug transporter. J Mol Microbiol Biotechnol 12: 197–209.
[13]	Mazurkiewicz P, Poelarends GJ, Driessen AJ, Konings WN (2004) Facilitated drug influx by an energy-uncoupled secondary multidrug transporter. J Biol Chem 279: 103–108.
[14]	Guan L, Kaback HR (2006) Lessons from lactose permease. Annu Rev Biophys Biomol Struct 35: 67–91.
[15]	Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E (2005) Crystal structure of a bacterial homologue of Na+/Cl–dependent neurotransmitter transporters. Nature 437: 215–223.
[16]	Shimamura T, Weyand S, Beckstein O, Rutherford NG, Hadden JM, et al. (2010) Molecular basis of alternating access membrane transport by the sodium-hydantoin transporter Mhp1. Science 328: 470–473.
[17]	Krishnamurthy H, Gouaux E (2012) X-ray structures of LeuT in substrate-free outward-open and apo inward-open states. Nature 481: 469–474.
[18]	Schuldiner S (2009) EmrE, a model for studying evolution and mechanism of ion-coupled transporters. Biochim Biophys Acta 1794: 748–762.
[19]	Sigal N, Fluman N, Siemion S, Bibi E (2009) The secondary multidrug/proton antiporter MdfA tolerates displacements of an essential negatively charged side chain. J Biol Chem 284: 6966–6971.
[20]	Brown MH, Skurray RA (2001) Staphylococcal multidrug efflux protein QacA. J Mol Microbiol Biotechnol 3: 163–170.
[21]	Huang Y, Lemieux MJ, Song J, Auer M, Wang DN (2003) Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science 301: 616–620.
[22]	Schaedler TA, van Veen HW (2010) A flexible cation binding site in the multidrug major facilitator superfamily transporter LmrP is associated with variable proton coupling. FASEB J 24: 3653–3661.
[23]	Venter H, Velamakanni S, Balakrishnan L, van Veen HW (2008) On the energy-dependence of Hoechst 33342 transport by the ABC transporter LmrA. Biochem Pharmacol 75: 866–874.
[24]	de Ruyter PG, Kuipers OP, de Vos WM (1996) Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin. Appl Environ Microbiol 62: 3662–3667.
[25]	von Heijne G (1989) Control of topology and mode of assembly of a polytopic membrane protein by positively charged residues. Nature 341: 456–458.
[26]	Dowhan W, Bogdanov M (2009) Lipid-dependent membrane protein topogenesis. Annu Rev Biochem 78: 515–540.
[27]	Venter H, Shilling RA, Velamakanni S, Balakrishnan L, Van Veen HW (2003) An ABC transporter with a secondary-active multidrug translocator domain. Nature 426: 866–870.
[28]	Putman M, Koole LA, van Veen HW, Konings WN (1999) The secondary multidrug transporter LmrP contains multiple drug interaction sites. Biochemistry 38: 13900–13905.
[29]	Steinfels E, Orelle C, Fantino JR, Dalmas O, Rigaud JL, et al. (2004) Characterization of YvcC (BmrA), a multidrug ABC transporter constitutively expressed in Bacillus subtilis. Biochemistry 43: 7491–7502.
[30]	Yu JL, Grinius L, Hooper DC (2002) NorA functions as a multidrug efflux protein in both cytoplasmic membrane vesicles and reconstituted proteoliposomes. J Bacteriol 184: 1370–1377.
[31]	Shapiro AB, Ling V (1995) Reconstitution of drug transport by purified P-glycoprotein. J Biol Chem 270: 16167–16175.
[32]	Balakrishnan L, Venter H, Shilling RA, van Veen HW (2004) Reversible transport by the ATP-binding cassette multidrug export pump LmrA: ATP synthesis at the expense of downhill ethidium uptake. J Biol Chem 279: 11273–11280.
[33]	Shilling R, Federici L, Walas F, Venter H, Velamakanni S, et al. (2005) A critical role of a carboxylate in proton conduction by the ATP-binding cassette multidrug transporter LmrA. FASEB J 19: 1698–1700.
[34]	Woebking B, Reuter G, Shilling RA, Velamakanni S, Shahi S, et al. (2005) Drug-lipid A interactions on the Escherichia coli ABC transporter MsbA. J Bacteriol 187: 6363–6369.
[35]	Zhou Y, Guan L, Freites JA, Kaback HR (2008) Opening and closing of the periplasmic gate in lactose permease. Proc Natl Acad Sci U S A 105: 3774–3778.
[36]	Zhou Y, Nie Y, Kaback HR (2009) Residues gating the periplasmic pathway of LacY. J Mol Biol 394: 219–225.
[37]	Abramson J, Smirnova I, Kasho V, Verner G, Kaback HR, et al. (2003) Structure and mechanism of the lactose permease of Escherichia coli. Science 301: 610–615.
[38]	Shinzawa-Itoh K, Aoyama H, Muramoto K, Terada H, Kurauchi T, et al. (2007) Structures and physiological roles of 13 integral lipids of bovine heart cytochrome c oxidase. EMBO J 26: 1713–1725.
[39]	Lange C, Nett JH, Trumpower BL, Hunte C (2001) Specific roles of protein-phospholipid interactions in the yeast cytochrome bc1 complex structure. EMBO J 20: 6591–6600.
[40]	Schmidt D, Cross SR, MacKinnon R (2009) A gating model for the archeal voltage-dependent K(+) channel KvAP in DPhPC and POPE:POPG decane lipid bilayers. J Mol Biol 390: 902–912.
[41]	Schmidt D, Jiang QX, MacKinnon R (2006) Phospholipids and the origin of cationic gating charges in voltage sensors. Nature 444: 775–779.
[42]	Long SB, Tao X, Campbell EB, MacKinnon R (2007) Atomic structure of a voltage-dependent K+ channel in a lipid membrane-like environment. Nature 450: 376–382.
[43]	Brohawn SG, del Marmol J, MacKinnon R (2012) Crystal structure of the human K2P TRAAK, a lipid- and mechano-sensitive K+ ion channel. Science 335: 436–441.
[44]	Gbaguidi B, Mazurkiewicz P, Konings WN, Driessen AJ, Ruysschaert JM, et al. (2004) Proton motive force mediates a reorientation of the cytosolic domains of the multidrug transporter LmrP. Cell Mol Life Sci 61: 2646–2657.
[45]	Hakizimana P, Masureel M, Gbaguidi B, Ruysschaert JM, Govaerts C (2008) Interactions between phosphatidylethanolamine headgroup and LmrP, a multidrug transporter: a conserved mechanism for proton gradient sensing? J Biol Chem 283: 9369–9376.
[46]	Kaback HR (1971) Bacterial membranes. Methods Enzymol 22: 99–120.
[47]	Woebking B, Velamakanni S, Federici L, Seeger MA, Murakami S, et al. (2008) Functional role of transmembrane helix 6 in drug binding and transport by the ABC transporter MsbA. Biochemistry 47: 10904–10914.
[48]	Breeuwer P, Drocourt J, Rombouts FM, Abee T (1996) A novel method for continuous determination of the intracellular pH in bacteria with the internally conjugated fluorescent probe 5 (and 6-)-carboxyfluorescein succinimidyl ester. Appl Environ Microbiol 62: 178–183.
[49]	Yokota A, Veenstra M, Kurdi P, van Veen HW, Konings WN (2000) Cholate resistance in Lactococcus lactis is mediated by an ATP-dependent multispecific organic anion transporter. J Bacteriol 182: 5196–5201.
[50]	Velamakanni S, Lau CH, Gutmann DA, Venter H, Barrera NP, et al. (2009) A multidrug ABC transporter with a taste for salt. PLoS One 4: e6137.
[51]	Doshi R, Woebking B, van Veen HW (2010) Dissection of the conformational cycle of the multidrug/lipidA ABC exporter MsbA. Proteins 78: 2867–2872.

Full-Text